Wed Mar 25, 2015 7:29am EDT

Israel-based VBL Therapeutics said a mid-stage study of its experimental brain cancer drug met the main goal of increasing overall survival.

The company said a combination of its drug, VBL-111, and Roche AG's cancer treatment, Avastin, significantly improved overall survival, compared with patients only given Avastin.

The company said it discontinued testing the drug as a monotherapy after nearly half the patients in the study saw the disease progress when given only VBL-111.